Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection

RATIONALE: Arikace is a liposomal amikacin preparation for aerosol delivery with potent Pseudomonas aeruginosa killing and prolonged lung deposition. OBJECTIVES: To examine the safety and efficacy of 28 days of once-daily Arikace in cystic fibrosis (CF) patients chronically infected with P aeruginos...

Descripción completa

Detalles Bibliográficos
Autores principales: Clancy, J P, Dupont, L, Konstan, M W, Billings, J, Fustik, S, Goss, C H, Lymp, J, Minic, P, Quittner, A L, Rubenstein, R C, Young, K R, Saiman, L, Burns, J L, Govan, J R W, Ramsey, B, Gupta, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Cystic Fibrosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756431/
https://www.ncbi.nlm.nih.gov/pubmed/23749840
http://dx.doi.org/10.1136/thoraxjnl-2012-202230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756431/
https://www.ncbi.nlm.nih.gov/pubmed/23749840
http://dx.doi.org/10.1136/thoraxjnl-2012-202230

Ejemplares similares